Piper Sandler analyst Joseph Catanzaro downgraded Turnstone Biologics (TSBX) to Neutral from Overweight with a price target of 40c, down from $3.75, after the company announced it is discontinuing all of its clinical studies evaluating TIDAL-01 and is exploring strategic alternatives. Piper removed all value for TIDAL-01 and downgraded the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX: